{"filings":[{"id":91248,"accession_number":"0001104659-26-054940","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Marker Therapeutics shareholders approve increase in authorized shares from 30M to 130M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved Charter Amendment to increase authorized common stock from 30M to 130M shares (10.9M for, 1.4M against).","Proposal to revise voting threshold for share changes failed; broker non-votes prevented passage.","All five director nominees re-elected; advisory vote on executive compensation passed.","Ratification of CBIZ CPAs as independent auditor for fiscal 2026 approved by shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101221,"accession_number":"0001104659-26-031309","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Marker Therapeutics FY2025 net loss $12.2M; cash $17M; APOLLO 66% ORR in NHL","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.2M vs $10.7M in 2024; R&D spend $11.8M (down from $13.5M).","Cash $17M at Dec 31, 2025; expected to fund ops through Q4 2026 without new grants.","Phase 1 APOLLO data: 66% objective response rate in relapsed NHL, 50% complete responses.","MT-601 pancreatic cancer program to initiate in Q2 2026; Nature Medicine publication Jan 2026.","New board member Kathryn Penkus Corzo appointed Nov 2025; Cellipont manufacturing collaboration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101220,"accession_number":"0001104659-26-012063","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["5.08","9.01"],"status":"ready","headline":"Marker Therapeutics sets 2026 annual meeting for May 1; shareholder proposals due March 9","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2026 Annual Meeting scheduled for May 1, 2026, moving more than 30 days from 2025 meeting date.","Shareholder proposals under Rule 14a-8 must be received by March 9, 2026, at company's Houston offices.","Record date and meeting details to be included in the upcoming proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117565,"accession_number":"0001104659-25-111940","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Marker Therapeutics reports Q3 net loss $2.0M; APOLLO study shows 66% ORR, 50% CR in NHL","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $17.6M + restricted $1.4M; runway into Q3 2026; raised ~$10M via ATM.","Net loss $2.0M (improved from $2.3M YoY); R&D $2.3M (down from $3.5M).","APOLLO study: 66% ORR, 50% CR in 12 relapsed NHL patients; durable responses (≥6 months in 5); dose expansion ongoing.","First patient dosed in OTS RAPID study (MT-401) for AML/MDS; cGMP manufacturing pact with Cellipont.","Appointed Kathryn Penkus Corzo to Board; two ASH presentations scheduled Dec 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":2443225.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117564,"accession_number":"0001104659-25-106669","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Marker Therapeutics appoints Kathryn Penkus Corzo to Board; CEO granted 250,000 options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kathryn Penkus Corzo appointed to Board effective Nov 1, 2025; she brings 30+ years of biopharma leadership.","Corzo currently President/COO of bit.bio; previously Head of Oncology Cell Therapy at Takeda Ventures.","Corzo received 147,611 stock options as non-employee director compensation, vesting over 36 months.","CEO Juan Vera granted 250,000 stock options, vesting annually over 4 years under the 2020 Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117563,"accession_number":"0001104659-25-096935","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Marker Therapeutics treats first patient in Phase 1 OTS MAR-T cell study; well tolerated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed at 100x10^6 cells in Phase 1 RAPID study evaluating MT-401 as Off-the-Shelf product.","No treatment-related adverse events observed in first patient; safety consistent with prior MAR-T cell data.","OTS product aims to accelerate time to treatment to as fast as 72 hours using healthy donor material.","Non-dilutive funding from FDA, NIH SBIR, and CPRIT supports OTS program without affecting cash runway.","APOLLO study in lymphoma reported 66% objective response rate and durable complete responses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134002,"accession_number":"0001104659-25-082783","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2025-08-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Marker Therapeutics Phase 1 APOLLO data: 66% ORR in NHL; 50% CR; dose expansion cleared","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["66% objective response rate in NHL patients (8/12), with 50% complete response (6/12) at doses 100-200×10^6 cells.","No dose-limiting toxicities or ICANS observed; two Grade 1 CRS events (no treatment required).","Safety Review Committee cleared 400×10^6 cells max dose for DLBCL dose expansion in CAR-T relapsed/ineligible patients.","HL patients (n=9) showed 78% ORR (7/9) with 11% CR; median 8 prior lines of therapy.","Webcast August 26, 2025 at 8:30 am ET; next data update expected H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134001,"accession_number":"0001104659-25-076834","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Marker Therapeutics changes auditor from Marcum to CBIZ CPAs; no disagreements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP resigned as auditor on August 6, 2025; CBIZ CPAs engaged for FY 2025.","Marcum's prior reports contained a going concern explanatory paragraph but no adverse opinions.","No disagreements or reportable events occurred during Marcum's tenure through 2025.","Change follows CBIZ's acquisition of Marcum's attest business effective November 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150742,"accession_number":"0001104659-25-060092","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Marker partners Cellipont for cGMP manufacturing of MT-601 for lymphoma trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Partnered with Cellipont Bioservices for cGMP manufacturing of MT-601, a MAR-T cell therapy for lymphoma in Phase 1 APOLLO study.","APOLLO study previously reported 78% objective response (7/9) and 44% complete response (4/9) at 4 weeks post MT-601 infusion.","Cellipont to provide technology transfer and cGMP manufacturing services over approximately nine months to support clinical supply.","Collaboration designed to enable potential pivotal trial and commercial readiness; Cellipont facility in The Woodlands, TX."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150741,"accession_number":"0001104659-25-057836","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Marker Therapeutics stockholders elect directors, approve say-on-pay, ratify auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Four director nominees elected: Eansor (4.1M for), Elms (4.1M), Knobil (4.1M), Vera (4.1M); broker non-votes 2.8M.","Advisory vote on named executive officer compensation passed: 4.45M for, 343K against, 13.9K abstain.","Ratification of Marcum LLP as independent auditor for FY2025: 7.49M for, 80.8K against, 53.9K abstain.","Total shares outstanding 11.3M; 67.43% quorum (7.63M shares present or proxy)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150740,"accession_number":"0001104659-25-050771","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Marker Therapeutics: lymphodepletion improves MT-601 cell expansion; enrollment surging","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 APOLLO study data: TCR sequencing shows MT-601 clones expanded/persisted at higher levels with lymphodepletion.","Prior data (Dec 2024): 7/9 patients (78%) objective response, 4 complete responses (44.4%); no DLTs or ICANS.","In first 5 months of 2025, enrolled and manufactured product for more patients than in all of 2024.","Company expects clinical data readout from APOLLO study later this year.","MT-601 targets lymphoma patients who relapsed after anti-CD19 CAR-T or for whom CAR-T is not an option."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169680,"accession_number":"0001104659-25-029666","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Marker Therapeutics FY2024 net loss $10.7M; MT-601 78% response rate in lymphoma","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.7M for FY2024 vs $8.2M in FY2023; R&D expense $13.5M, G&A $4.2M.","Cash and equivalents $19.2M at Dec 31, 2024; funds operations into Q1 2026 without additional grants.","Phase 1 APOLLO study: MT-601 (neldaleucel) achieved 78% objective response rate (7/9) with 44.4% complete responses; well-tolerated.","Secured $13M+ in non-dilutive funding from CPRIT ($9.5M) and NIH SBIR ($2M) for pancreatic and lymphoma programs.","December 2024 private placement raised $16.1M from new and existing investors including Blue Owl, NEA, Aisling Capital."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":349104.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169679,"accession_number":"0001104659-25-028821","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Marker Therapeutics stockholders approve issuance of 8.28M warrant shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At special meeting on March 21, 2025, 4,158,543 shares (38.83% of outstanding) represented.","Proposal passed: 3,483,897 for, 668,383 against, 6,263 abstained.","Approves issuance of up to 5,031,250 shares under Series A Warrants and 3,247,445 under Series B Warrants.","Total authorized warrant shares: 8,278,695, approximately 77% of 10.7M outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.15,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169676,"accession_number":"0001104659-25-020405","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K/A","filed_at":"2025-03-04T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Marker Therapeutics corrects option grant date to Feb 12, 2025; awards options to CEO and directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Dr. Juan Vera receives 50,000 stock options vesting annually over three years.","Non-employee directors David Eansor, Katherine Knobil, Steven Elms each receive 30,000 options.","Amendment corrects prior filing: grant date changed from Feb 12, 2024 to Feb 12, 2025.","All options are under the 2020 Omnibus Stock Ownership Plan and standard award agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169678,"accession_number":"0001104659-25-015224","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Marker Therapeutics grants 50,000 CEO options and 30,000 options each to three non-employee directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Juan Vera awarded 50,000 stock options vesting annually over three years under 2020 Plan.","Non-employee directors David Eansor, Katherine Knobil, and Steven Elms each receive 30,000 options with same vesting.","Awards approved by Compensation Committee and Board on February 12, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169677,"accession_number":"0001104659-25-007574","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director John Wilson resigns from Marker Therapeutics board on Jan. 24, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Wilson resigned from the Board of Directors effective January 24, 2025.","No reason for resignation or replacement director disclosed in the filing.","No other compensatory or leadership changes reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186737,"accession_number":"0001104659-24-131322","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Marker Therapeutics closes $16.1M private placement of stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$16.1M from sale of 1,783,805 shares, Series A warrants (5,031,250 shares at $4.00/sh), and pre-funded warrants (3,248,445 shares at $0.001/sh).","Closed December 23, 2024; net proceeds for general corporate purposes and working capital.","Company must seek stockholder approval for warrant share issuance within 90 days; ~27% of stockholders agreed to vote in favor.","Registration rights agreement requires resale registration statement filed by January 14, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186736,"accession_number":"0001104659-24-130002","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Marker Therapeutics: 78% objective response in APOLLO study; raises $16.1M in private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 APOLLO: 78% of patients (7/9) achieved objective response; 44.4% complete response at first assessment.","MT-601 well tolerated; no ICANS observed, one Grade 1 CRS; no dose-limiting toxicities.","Private placement raises $16.1M gross proceeds; 5,031,250 shares at $3.20 with warrants at $4.03.","Proceeds to support clinical advancement of MT-601 in relapsed lymphoma after CAR-T failure.","New and existing investors: Blue Owl, NEA, and Aisling Capital participated in the financing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186735,"accession_number":"0001104659-24-129181","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Marker Therapeutics awarded $9.5M CPRIT grant for MT-601 in pancreatic cancer study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received $9.5M non-dilutive grant from CPRIT to support Phase 1 PANACEA study of MT-601 in metastatic pancreatic cancer.","Also received $2M NIH SBIR grant; total non-dilutive funding exceeds $30M from FDA, NIH, and CPRIT.","Clinical program initiation for MT-601 in pancreatic cancer expected in 2025.","Preliminary data from prior multiTAA-specific T cell study showed 1 CR, 3 PRs, 6 SD in 13 pancreatic cancer patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186734,"accession_number":"0001104659-24-119077","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Marker Therapeutics reports Q3 2024 net loss of $2.3M; receives $4M NIH grants","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents of $9.0M as of Sept 30, 2024; expects to fund operations into October 2025.","Net loss from continuing operations improved to $2.3M (Q3 2024) from $3.0M (Q3 2023).","R&D expenses rose to $3.5M (Q3 2024) vs $2.0M (Q3 2023) due to increased clinical trial activity.","Received two $2M SBIR grants from NIH ($4M total) to support MT-601 trials in lymphoma and pancreatic cancer.","Phase 1 APOLLO study of MT-601 in lymphoma continues enrolling; expects preliminary data by end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":4339317.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203297,"accession_number":"0001104659-24-089704","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Marker Therapeutics Q2 net loss narrows to $2.2M; reports positive MT-601 APOLLO data, receives $2M NIH grant","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops $2.2M vs $4.1M YoY; cash $7.8M expected to fund into Q4 2025.","MT-601 APOLLO study shows objective responses in 3 of 3 lymphoma patients; no CRS or ICANS observed.","Awarded $2M NIH SBIR grant to support MT-601 lymphoma trial.","MT-401-OTS IND cleared for AML/MDS; clinical program initiation expected Q4 2024.","R&D expenses $2.3M (flat); G&A decreased to $1.1M from $2.5M YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":2413297.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203296,"accession_number":"0001104659-24-088054","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Marker Therapeutics awarded $2M NIH SBIR grant for MT-601 Phase 1 in CAR-relapsed NHL","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Awarded $2 million non-dilutive grant from NIH SBIR to support Phase 1 APOLLO study of MT-601 in NHL patients relapsed after anti-CD19 CAR T therapy.","Grant based on preliminary clinical data (Sept 2023) and non-clinical data (May 2023) showing anti-tumor activity of MT-601.","Company has now received over $19 million in total non-dilutive funding proceeds.","APOLLO study evaluates multiTAA-specific T cell product; initial patients showed objective responses with no CRS or ICANS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219652,"accession_number":"0001104659-24-070830","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Marker Therapeutics terminates ATM equity facility; shareholders elect board, approve auditor and pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders elected five directors: D. Eansor, S. Elms, J. Wilson, J. Vera, K. Knobil; each with >3M votes for.","Advisory 'say-on-pay' vote passed 2,931,920 for vs 276,480 against, with 14,000 abstentions.","Ratification of Marcum LLP as auditor for FY2024 passed 5,137,819 for vs 494,128 against, with 14,366 abstentions.","Terminated ATM equity facility with Cantor Fitzgerald & Co. and RBC Capital Markets; facility allowed up to $75M in stock sales, no termination penalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219651,"accession_number":"0001104659-24-062001","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Marker Q1 net loss narrows to $2.4M; MT-601 shows durable CRs in APOLLO trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $2.4M in Q1 2024 vs $4.9M in Q1 2023; cash $11.3M expected to fund into Q4 2025.","Three patients treated with MT-601: 2 complete responses (one >9 months after CAR-T relapse) and 1 partial response; well tolerated.","MT-601 received nonproprietary name 'neldaleucel' from USAN/INN; more data expected H2 2024.","MT-401-OTS IND cleared for AML/MDS; clinical initiation expected H2 2024; secured $2M NIH SBIR funding.","R&D expenses $2.6M, G&A $1.2M, both down YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219650,"accession_number":"0001104659-24-044496","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2024-04-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Marker Therapeutics: MT-601 shows durable CR in lymphoma patient 9 months post-CAR T failure; 3/3 objective responses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First APOLLO participant with DLBCL who relapsed after CAR T remains in complete response 9 months after MT-601 treatment.","Second participant with transformed follicular NHL achieved CR at 8 weeks and remains in CR at 3 months.","Third participant with DLBCL (CAR T-ineligible) achieved partial response at 8 weeks with lesion shrinkage.","All three patients tolerated treatment well; no cytokine release syndrome or neurotoxicity reported.","Data presented at 11th Global Summit on Hematologic Malignancies on April 6, 2024 by City of Hope PI Dr. Shouse."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239451,"accession_number":"0001104659-24-038533","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Marker Therapeutics reports FY 2023 net loss of $8.2M, down from $29.9M; cash runway into Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $8.2M in FY 2023 from $29.9M in FY 2022; R&D spend cut to $10.4M from $12.0M.","Cash and equivalents $15.1M at Dec 31, 2023; company expects funding into Q4 2025 via grant drawdowns.","First lymphoma patient treated with MT-601 achieved sustained complete response >6 months after CAR T relapse.","Completed $19M asset sale to Cell Ready reducing annual overhead ~$11M; secured $2M NIH grant for AML program.","Appointed Juan Vera as CEO/Principal Financial Officer and Monic Stuart as CMO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239450,"accession_number":"0001104659-24-029638","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"Marker Therapeutics terminates $25M equity purchase agreement with Lincoln Park Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Purchase Agreement with Lincoln Park Capital Fund effective March 1, 2024.","Only 12,500 shares were sold under the agreement, generating ~$33,000 in proceeds.","Company projects financial runway through Q4 2025; no immediate capital need.","No early termination penalties; 1.8M commitment shares previously issued to LPC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239449,"accession_number":"0001104659-24-027293","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Marker Therapeutics enters $750K manufacturing deal with director-owned CDMO Cell Ready","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["3-year Master Services Agreement with Cell Ready LLC, owned by director/shareholder John Wilson.","Work Order #1 for GMP drug product for MT-401 and/or MT-601; projected sum ≤$750K for Q1 2024.","Agreement includes customary reps, warranties, and indemnification; either party may terminate for breach or insolvency.","Additional work orders expected for the remainder of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239448,"accession_number":"0001104659-24-002086","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Marker Therapeutics prioritizes MT-601 for CAR T-relapsed lymphoma, discontinues patient-specific AML program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MT-601 for DLBCL patients who relapsed after CAR T: first APOLLO participant maintained complete response at 6 months.","Patient-specific AML program (ARTEMIS) discontinued due to manufacturing delays; shift to ready-to-use MT-401 from healthy donors.","Non-dilutive funding secured for off-the-shelf AML program; cash runway extended into Q4 2025.","Pancreatic cancer Phase 1 IND cleared but advancement pending additional non-dilutive funding.","MultiTAA T cell therapies shown safe in over 200 patients; no treatment-related adverse events in APOLLO or ARTEMIS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256974,"accession_number":"0001104659-23-124869","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Marker Therapeutics reports sustained complete response in Phase 1 lymphoma patient at 6 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DLBCL patient who failed anti-CD19 CAR T and 3 prior therapies achieved CR at 8 weeks and remains in CR at 6 months after MT-601.","MT-601 is a multiTAA-specific T cell therapy, non-genetically engineered, well-tolerated without severe CAR T side effects like neurotoxicity.","Up to 60% of lymphoma patients relapse within one year after CAR T; this patient had relapsed within 90 days yet maintained response.","Company has enrolled additional patients in APOLLO study to replicate results; City of Hope is the trial site.","Non-clinical data shows MT-601 can eradicate lymphoma cells resistant to anti-CD19 CAR T in vitro."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256973,"accession_number":"0001104659-23-119946","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2023-11-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Marker Therapeutics terminates Interim CFO; CEO assumes principal financial officer role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["On Nov 17, 2023, Marker terminated Danforth Advisors consulting agreement, effective Jan 16, 2024.","Eliot M. Lurier ceased as Interim CFO and Principal Financial and Accounting Officer immediately.","CEO Juan Vera appointed as Principal Financial and Accounting Officer effective Nov 17, 2023.","No replacement CFO has been announced; CEO will handle financial officer duties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256972,"accession_number":"0001104659-23-116364","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Marker Therapeutics reports Q3 net loss $3.0M; complete response in first MT-601 lymphoma patient","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.0M for Q3 2023 vs $6.9M in Q3 2022; R&D expenses down to $2.0M from $3.6M.","First lymphoma patient treated with MT-601 in Phase 1 APOLLO trial achieved complete metabolic response after failing CAR T therapy.","MT-401 (zedenoleucel) received Orphan Drug Designation from EMA for AML; clinical trial for MT-401 off-the-shelf expected in 2024.","Cash and cash equivalents of $17.5M as of September 30, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":2254601.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274313,"accession_number":"0001104659-23-099485","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2023-09-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Marker Therapeutics reports complete response in first lymphoma patient treated with MT-601 after CAR T relapse","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First APOLLO trial patient with DLBCL, after 4 prior therapies including CAR T, achieved complete metabolic response at 8 weeks post 2nd MT-601 infusion.","MT-601 dosed at 200 million cells without prior lymphodepletion; no treatment-related adverse events above Grade 1.","Up to 60% of CAR T patients relapse within one year, underscoring potential of MT-601 in this setting.","Phase 1 APOLLO trial continues to enroll additional participants to evaluate safety and efficacy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274312,"accession_number":"0001104659-23-091425","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Marker Therapeutics Q2 net income $2.5M; Cell Ready deal extends cash runway into Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $2.5M vs net loss of $9.2M in Q2 2022; cash and equivalents $18.1M.","Non-dilutive agreement with Cell Ready provides ~$19M cash and reduces annual operating expenses by ~$11M.","Appointed Juan Vera as CEO and Monic Stuart as CMO to lead restructuring and clinical advancement.","NIH awarded $2M SBIR grant for MT-401 AML program; EMA granted Orphan Drug Designation for MT-401.","First lymphoma patient dosed with MT-601 in Phase 1 APOLLO trial with no treatment-related adverse events."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":1996995.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274311,"accession_number":"0001104659-23-088072","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Marker Therapeutics reports non-clinical proof-of-concept data for MT-401 OTS, expects first patient treatment H1 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-clinical data: MT-401 OTS killed AML cells in vitro with 2/8 HLA match, significantly reducing THP-1 cell growth.","FDA cleared clinical protocol for MT-401 OTS in relapsed/refractory AML; inventory of 8 donor lines established.","Single donor could treat ~40 patients; product stable >1 year; first patient treatment expected H1 2024.","OTS strategy aims to reduce manufacturing cost and turnaround time to as little as 72 hours."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274310,"accession_number":"0001104659-23-079310","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2023-07-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Marker Therapeutics' MT-401 receives EMA Orphan Drug Designation for AML","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["EMA granted Orphan Drug Designation for zedenoleucel (MT-401) for acute myeloid leukemia (AML).","MT-401 is a non-genetically modified multiTAA-specific T cell therapy targeting four AML-associated antigens.","Phase 2 trial ongoing for relapsed AML after allogeneic HSCT; FDA also granted orphan designation in 2020.","Benefits include 10-year EU market exclusivity post-approval, reduced regulatory fees, and scientific advice.","Relapsed AML after HSCT has median survival <1 year, underscoring the need for new therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274309,"accession_number":"0001104659-23-077598","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2023-07-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Marker Therapeutics CAO departs; appoints Eliot Lurier as Interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Loiacono, Chief Accounting Officer, separated effective June 30, 2023.","Company agreed to provide severance benefits consistent with employment agreement upon execution of release.","Eliot M. Lurier appointed Interim CFO effective June 30; serves via Danforth Advisors consulting agreement.","Mr. Lurier, age 65, has served as consultant to life science companies through Danforth since July 2021.","No family relationships or material transactions between Lurier and company officers/directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291554,"accession_number":"0001104659-23-077074","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2023-06-30T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Marker Therapeutics completes $19M sale of manufacturing facilities to Cell Ready, exits manufacturing operations","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Completed disposition of manufacturing facilities and equipment to Cell Ready for $19M on June 26, 2023.","Transaction includes assignment of leases and sale of equipment; Cell Ready to offer employment to ~50 Marker employees.","Pro forma results show net loss per share improvement: Q1 2023 by $0.01, FY2022 by $1.18, FY2021 by $2.11.","Pro forma cash and cash equivalents increased to $25.2M from $6.4M as of March 31, 2023.","John Wilson, Marker board member, is CEO and sole member of Cell Ready, creating a related-party transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291553,"accession_number":"0001104659-23-074513","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2023-06-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Marker Therapeutics reports non-clinical data showing MT-401 + HMA synergy; awarded $2M NIH grant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-clinical in vitro data: MT-401 after HMA (5'-Azacytidine) significantly decreased AML THP-1 cell growth vs. either agent alone, suggesting synergy.","NIH SBIR grant of $2 million will fund a nationwide multi-center Phase 2b trial of MT-401 with HMA pre-treatment in AML patients post-HSCT.","MT-401 targets four antigens (Survivin, PRAME, WT-1, NY-ESO-1); HMA upregulated Survivin expression in AML cells.","Company plans to incorporate findings into current AML clinical study; revised design details expected in Q3 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291552,"accession_number":"0001104659-23-070151","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2023-06-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Marker Therapeutics treats first lymphoma patient in Phase 1 APOLLO trial of MT-601","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed at 200 million cells; no treatment-related adverse events after 18 days.","Trial enrolls up to 30 patients across 8 U.S. sites for lymphoma patients relapsed after or ineligible for anti-CD19 CAR T therapy.","MT-601 targets six tumor antigens; prior TACTAL study showed durable responses with a five-antigen product.","Nonclinical data from May 2023 showed MT-601 inhibited lymphoma cells regardless of CD19 expression and overcame CAR T resistance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291551,"accession_number":"0001104659-23-069896","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Marker Therapeutics announces 2023 annual meeting voting results; all director nominees elected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Five director nominees elected with votes for ranging from 2,473,599 to 2,500,415; broker non-votes 3,193,097.","Advisory approval of named executive officer compensation: 2,347,263 for, 321,791 against, 27,721 abstained.","Preferred frequency of say-on-pay set to one year after 2,535,976 votes for one year.","Ratification of Marcum LLP as auditor: 5,760,786 for, 109,958 against, 19,128 abstained.","Total shares outstanding 8,798,829; 66.94% present at meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291550,"accession_number":"0001104659-23-066311","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2023-05-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Marker Therapeutics reports pre-clinical data showing MT-601 kills CD19 CAR T refractory lymphoma cells","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In vitro, MT-601 completely inhibited growth of lymphoma cells resistant to CD19 CAR T therapy after 3 weeks.","Initial CAR T administration eliminated 98% of lymphoma cells; resistant population emerged; MT-601 overcame resistance.","MT-601 targets six antigens (including WT-1) vs. five in earlier TACTAL study, potentially offering more durable responses.","FDA cleared IND for MT-601; Phase 1 trial in relapsed non-Hodgkin lymphoma initiated Q1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291549,"accession_number":"0001104659-23-056863","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Marker Therapeutics names Monic Stuart, M.D., as new CMO; she brings 20+ years drug development experience","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Stuart appointed CMO effective May 8, 2023; will oversee multiTAA-specific T cell pipeline including MT-401 Phase 2 ARTEMIS study.","Over 20 years experience; previously interim CMO at multiple biotechs, VP Clinical Development at Geron, Senior Medical Director at Genentech.","She is a transplant physician with expertise in AML and lymphoma, aligning with Marker's prioritized clinical programs.","Dr. Stuart will lead clinical strategy for MT-401 in AML and MT-601 in non-Hodgkin lymphoma and pancreatic cancer.","CEO Juan Vera cited her deep industry experience and clinical background as key to advancing pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291548,"accession_number":"0001104659-23-053509","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Marker Therapeutics sells manufacturing assets for $19M, appoints Juan Vera as CEO, extends runway to end of 2025","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["CellReady to purchase Marker's manufacturing assets for ~$19M in cash; annual overhead reduced by ~$11M; closing targeted June 26, 2023.","CEO Peter Hoang resigns effective May 1; board appoints Juan Vera (formerly COO/CSO) as President and CEO.","Non-dilutive deal extends Marker's financial runway through year-end 2025; net benefit estimated at ~$42M.","Clinical priorities: MT-601 in NHL trial, MT-401 in post-transplant AML; data expected H2 2024.","Board member David Laskow-Pooley will not stand for reelection at 2023 annual meeting, term expires then."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312329,"accession_number":"0001104659-23-035380","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2023-03-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Marker Therapeutics reports FY2022 net loss of $29.9M; cash runs into Q3 2023; suspends frank relapse enrollment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $29.9M for FY2022, improved from $41.9M in prior year.","Cash and cash equivalents $11.8M at Dec 31, 2022; expected to fund operations into Q3 2023.","Suspended enrollment of frank relapse patients in ARTEMIS trial after no objective responses; re-evaluating modifications.","MT-401 showed MRD+ responses: one patient bridged to transplant, another with 70% PCR reduction; data expected H2 2023.","Wilson Wolf services agreement provided $8M upfront; Lincoln Park equity facility for up to $25M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312328,"accession_number":"0001104659-23-033300","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2023-03-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Chief Medical Officer Mythili Koneru resigns effective April 9, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mythili Koneru notified Marker Therapeutics of her resignation as Chief Medical Officer, effective April 9, 2023.","No replacement or interim successor has been announced by the company.","The departure removes a key clinical oversight role from the biotech firm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312327,"accession_number":"0001104659-23-007019","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2023-01-26T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Marker Therapeutics files amendment for 1-for-10 reverse stock split and authorized share reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Certificate of Amendment on January 26, 2023, effective 5:00 p.m. ET that day.","Reverse stock split combines every 10 shares into 1, with no fractional shares issued.","Authorized shares reduced from 300,000,000 to 30,000,000 at same par value of $0.001.","Common stock will begin trading on Nasdaq Capital Market on a split-adjusted basis on January 27, 2023.","Adjustments made to all outstanding stock options, warrants, and equity compensation reserves."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330888,"accession_number":"0001104659-22-126446","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2022-12-13T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Marker Therapeutics enters $25M common stock purchase agreement with Lincoln Park Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $25M in common stock may be sold to Lincoln Park over 24 months at Marker's discretion.","Pricing based on prevailing market prices; no upper limit per share and no warrants issued.","Marker issued 1,804,098 commitment shares to Lincoln Park as consideration.","Lincoln Park covenants not to engage in short selling or hedging of Marker's stock.","Proceeds to fund Phase 2 ARTEMIS trial, lymphoma/pancreatic programs, and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330887,"accession_number":"0001104659-22-120986","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2022-11-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA clears Marker Therapeutics IND for MT-601 to treat pancreatic cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for MT-601, a six-antigen T cell therapy for locally advanced unresectable or metastatic pancreatic cancer.","Phase 1 trial planned for 2023, combining MT-601 with front-line chemotherapy.","New manufacturing process reduces production time from >30 days to 9 days with 90% fewer interventions.","Interim TACTOPS study data showed multiTAA therapy plus chemo yielded better-than-expected clinical responses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330886,"accession_number":"0001104659-22-117148","cik":1094038,"company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Marker Therapeutics Q3 net loss narrows to $6.9M; FDA grant awarded for AML trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.9M in Q3 2022, compared to $12.4M loss in Q3 2021.","Cash and equivalents $18.1M as of Sept 30, 2022; grant income $1.0M, related party service revenue $2.95M.","Awarded $2M FDA Orphan Products Grant to support Phase 2 ARTEMIS trial of MT-401 in post-transplant AML.","All six patients in Cohorts 4/5 treated with new manufacturing process; no DLTs; efficacy data expected by year-end.","FDA cleared IND for Phase 1 MT-601 in relapsed/refractory non-Hodgkin lymphoma; first patient expected Q1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":5704401.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":24176034.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-11-10T23:59:59+00:00|330886"}